Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
pbi-shRNA EWS/FLI1 Type 1 Lipoplex in Advanced Ewing's Sarcoma
NCT02736565Phase 1Completed
- Sponsor
- Gradalis, Inc.
- Start
- Oct 2016
- Primary completion
- Aug 2019
- Modality
- Gene Editing, Lipid-based Nanoparticles, Viral-delivered RNAi
- Countries
- 1
01
Overview
Phase 1, open-label trial of pbi-shRNA EWS/FLI1 Type 1 Lipoplex in Ewing sarcoma (8 cohorts), sponsored by Gradalis, Inc. Primary endpoints: Number of Participants with Treatment-Related Adverse Events as Assessed by CTCAE v4.0 up to 13 months and Maximum Tolerated Dose up to 4 weeks. Started Oct 2016; status: completed.
02
Drugs
pbi-shRNA EWS/FLI1 Type 1 Lipoplex
03
Conditions
Ewing sarcoma
Beyond the preview
Go deeper on NCT02736565.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02736565.